<DOC>
	<DOC>NCT03052517</DOC>
	<brief_summary>This study is a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study is to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when added to the Global Initiative for Asthma (GINA) steps 3, 4, and 5 standard-of-care (SoC) asthma therapy (GINA 2016), in patients with moderate-to- severe asthma.</brief_summary>
	<brief_title>Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients completing a prior Phase 3 study of QAW039: Informed consent and assent (if applicable). Completion of the Treatment Period (on blinded study drug) of a prior Phase 3 study of QAW039. Patient is able to safely continue into the study as judged by the investigator. Patients who have not previously participated in a study of QAW039: Written informed consent. A diagnosis of asthma,uncontrolled on GINA 3/4/5 asthma medication. Evidence of airway reversibility or airway hyper reactivity. FEV1 of ≥40% and ≤85% of the predicted normal value. An ACQ score ≥1.5 prior to entering the study. Patients completing a prior phase 3 study of QAW039: Pregnant or nursing (lactating) women. Women of childbearing potential unless they are using basic methods of contraception during dosing of study drug Patients who did not complete the Treatment Period on blinded study drug of the prior QAW039 study they participated in. Inability to comply with all study requirements. Patient who experienced a serious and drugrelated AE in the prior QAW039 study they participated in. Patient who developed a condition during the prior study that would have excluded them from participation in that study. Patients who have not previously participated in a study of QAW039: Use of other investigational drugs within 5 halflives of study entry, or within 30 days, whichever is longer. Subjects who have participated in another trial of QAW039. A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female). History of malignancy with the exception of local basal cell carcinoma of the skin Pregnant or nursing (lactating) women. Serious comorbidities. Patients on greater than 20 mg of simvastatin&gt; 40 mg of atorvastatin, &gt;40 mg of pravastatin, or &gt;2 mg of pitavastatin. Statin doses less than or equal to these doses as well as other statins will be permitted during the study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma, QAW039</keyword>
</DOC>